Lumasiran
- Generic Name
- Lumasiran
- Brand Names
- Oxlumo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1834610-13-7
- Unique Ingredient Identifier
- RZT8C352O1
- Background
Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. These patients experience frequent kidney stones, nephrocalcinosis, and renal failure.
...
- Indication
Lumasiran is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients.
- Associated Conditions
- Primary Hyperoxaluria Type 1 (PH1)
- Associated Therapies
- -
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 50
- Registration Number
- NCT06225544
- Locations
- 🇩🇪
Charite Universtiätsmedizin, Berlin, Germany
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05161936
- Locations
- 🇬🇧
Clinical Trial Site, Leeds, United Kingdom
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT04152200
- Locations
- 🇦🇪
Clinical Trial Site, Dubai, United Arab Emirates
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
- Conditions
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Alnylam Pharmaceuticals
- Registration Number
- NCT04125472
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
- Conditions
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03905694
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
- Conditions
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT03681184
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT03350451
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1
- Conditions
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT02706886
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.